[HTML][HTML] Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - Pharmaceutics, 2023 - mdpi.com
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - …, 2023 - search.proquest.com
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - …, 2023 - europepmc.org
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, LJ Brstilo, A Sancho Araiz, M Molina… - 2023 - lareferencia.info
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
[HTML][HTML] Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - …, 2023 - ncbi.nlm.nih.gov
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, LJ Brstilo, A Sancho Araiz, M Molina… - 2023 - datosdeinvestigacion.conicet.gov.ar
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, LJ Brstilo, A Sancho Araiz, M Molina… - 2023 - notablesdelaciencia.conicet.gov.ar
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases.
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - …, 2023 - search.ebscohost.com
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, L Brstilo, A Sancho-Araiz, M Molina… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
N Riva, LJ Brstilo, A Sancho Araiz, M Molina… - 2023 - ri.conicet.gov.ar
Background: Limited pharmacotherapy and the failure of conventional treatments in complex
pathologies in children lead to increased off-label use of rituximab. We aimed to …
pathologies in children lead to increased off-label use of rituximab. We aimed to …